Tempus AI Inc. shares surged over 16% on Wednesday following the announcement of a significant multi-year strategic collaboration with pharmaceutical giant AstraZeneca and Pathos AI to develop a groundbreaking multimodal foundation model in oncology.
The agreement, valued at $200 million in data licensing and model development fees, will utilize Tempus' extensive de-identified oncology database to drive biological and clinical insights, discover novel drug targets, and accelerate therapeutic development for the broader oncology community.
Strategic Partnership Details
The collaboration represents an expansion of the existing partnership between Tempus and AstraZeneca established in 2021. Under the new agreement, the three companies will jointly develop an advanced AI model that aims to transform cancer drug discovery and clinical development processes.
"Cancer drug discovery and clinical development are being transformed by the ability to analyze vast amounts of rich data using artificial intelligence," said Jorge Reis-Filho, Chief AI and Data Scientist for Oncology R&D at AstraZeneca.
The completed model will be accessible to all three partners, enabling each to enhance their independent patient care initiatives and research capabilities. This shared access model represents a collaborative approach to addressing complex challenges in oncology.
Advancing Precision Medicine Through AI
Eric Lefkofsky, founder and CEO of Tempus AI, emphasized the transformative potential of this collaboration: "Generative AI and the emergence of large multimodal models is the final catalyst needed to usher in precision medicine in oncology at scale."
Lefkofsky noted that Tempus has invested billions of dollars over the past decade to collect the necessary data for such a foundation model. "We look forward to working with AstraZeneca and Pathos to apply AI-enabled solutions to advance therapies in an effort to help patients live longer and healthier lives," he added.
The partnership comes at a critical juncture in oncology research, where the integration of artificial intelligence with comprehensive clinical and molecular data has the potential to dramatically accelerate drug discovery timelines and improve treatment precision.
Market Impact and Investor Response
The announcement triggered significant investor enthusiasm, with Tempus shares climbing approximately 16.5% to $50.37 on Wednesday. The stock has demonstrated strong performance in 2025, gaining approximately 46% year-to-date.
Tempus AI, which went public in 2024, has attracted attention from prominent investors, including former House Speaker Nancy Pelosi, who purchased call options in the company in January 2025. These options, with a strike price of $20 and expiration in January 2026, have already seen substantial appreciation.
Wall Street analysts maintain a bullish outlook on Tempus stock, with an average 12-month price target of $62.33 according to TipRanks data, representing a potential 25.41% increase from current levels. BTIG analyst Mark Massaro recently initiated coverage with a 'Buy' rating and a $60 price target.
Technological Foundations and Future Applications
The multimodal foundation model being developed will integrate various data types, including genomic, transcriptomic, clinical, and imaging data, to create a comprehensive platform for oncology research and development.
This approach represents a significant advancement over traditional single-modality AI models, potentially enabling researchers to identify complex patterns and relationships that might otherwise remain undetected.
The collaboration underscores the growing importance of AI-driven approaches in pharmaceutical research and development, particularly in oncology where treatment outcomes can vary significantly based on individual patient characteristics and tumor profiles.
As precision medicine continues to evolve, partnerships like this one between Tempus, AstraZeneca, and Pathos AI may establish new paradigms for how cancer therapies are discovered, developed, and deployed to address unmet medical needs.
